Chuangqi Wang1, Timothy E Schlub2, Wen Han Yu3, C Sabrina Tan4, Karl Stefic5, Sara Gianella6, Davey M Smith6,7, Douglas A Lauffenburger1, Antoine Chaillon6, Boris Julg8. 1. Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA. 2. University of Sydney, Faculty of Medicine and Health, Sydney School of Public Health, Sydney, New South Wales, Australia. 3. Bill & Melinda Gates Medical Research Institute, Cambridge, Massachusetts, USA. 4. Division of Infectious Diseases, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. 5. Department of Virology, Tours University Hospital, Tours, France. 6. Division of Infectious Diseases and Global Public Health, University of California-San Diego, San Diego, California, USA. 7. VA San Diego Healthcare System, San Diego, California, USA. 8. Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, Massachusetts, USA.
Abstract
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) sequence diversity and the presence of archived epitope muta-tions in antibody binding sites are a major obstacle for the clinical application of broadly neutralizing antibodies (bNAbs) against HIV-1. Specifically, it is unclear to what degree the viral reservoir is compartmentalized and if virus susceptibility to antibody neutralization differs across tissues. METHODS: The Last Gift cohort enrolled 7 people with HIV diagnosed with a terminal illness and collected antemortem blood and postmortem tissues across 33 anatomical compartments for near full-length env HIV genome sequencing. Using these data, we applied a Bayesian machine-learning model (Markov chain Monte Carlo-support vector machine) that uses HIV-1 envelope sequences and approximated glycan-occupancy information to quantitatively predict the half-maximal inhib-itory concentrations (IC50) of bNAbs, allowing us to map neutralization resistance pattern across tissue reservoirs. RESULTS: Predicted mean susceptibilities across tissues within participants were relatively homogenous, and the susceptibility pattern observed in blood often matched what was predicted for tissues. However, selected tissues, such as the brain, showed ev-idence of compartmentalized viral populations with distinct neutralization susceptibilities in some participants. Additionally, we found substantial heterogeneity in the range of neutralization susceptibilities across tissues within and between indi-viduals, and between bNAbs within individuals (standard deviation of log2(IC50) >3.4). CONCLUSIONS: Blood-based screening methods to determine viral susceptibility to bNAbs might underestimate the presence of resistant viral variants in tissues. The extent to which these resistant viruses are clinically relevant, that is, lead to bNAb therapeutic failure, needs to be further explored.
BACKGROUND: Human immunodeficiency virus type 1 (HIV-1) sequence diversity and the presence of archived epitope muta-tions in antibody binding sites are a major obstacle for the clinical application of broadly neutralizing antibodies (bNAbs) against HIV-1. Specifically, it is unclear to what degree the viral reservoir is compartmentalized and if virus susceptibility to antibody neutralization differs across tissues. METHODS: The Last Gift cohort enrolled 7 people with HIV diagnosed with a terminal illness and collected antemortem blood and postmortem tissues across 33 anatomical compartments for near full-length env HIV genome sequencing. Using these data, we applied a Bayesian machine-learning model (Markov chain Monte Carlo-support vector machine) that uses HIV-1 envelope sequences and approximated glycan-occupancy information to quantitatively predict the half-maximal inhib-itory concentrations (IC50) of bNAbs, allowing us to map neutralization resistance pattern across tissue reservoirs. RESULTS: Predicted mean susceptibilities across tissues within participants were relatively homogenous, and the susceptibility pattern observed in blood often matched what was predicted for tissues. However, selected tissues, such as the brain, showed ev-idence of compartmentalized viral populations with distinct neutralization susceptibilities in some participants. Additionally, we found substantial heterogeneity in the range of neutralization susceptibilities across tissues within and between indi-viduals, and between bNAbs within individuals (standard deviation of log2(IC50) >3.4). CONCLUSIONS: Blood-based screening methods to determine viral susceptibility to bNAbs might underestimate the presence of resistant viral variants in tissues. The extent to which these resistant viruses are clinically relevant, that is, lead to bNAb therapeutic failure, needs to be further explored.
Authors: Marie-Angélique De Scheerder; Bram Vrancken; Simon Dellicour; Timothy Schlub; Eunok Lee; Wei Shao; Sofie Rutsaert; Chris Verhofstede; Tessa Kerre; Thomas Malfait; Dimitri Hemelsoet; Marc Coppens; Annemieke Dhondt; Danny De Looze; Frank Vermassen; Philippe Lemey; Sarah Palmer; Linos Vandekerckhove Journal: Cell Host Microbe Date: 2019-08-27 Impact factor: 21.023
Authors: Katharine J Bar; Michael C Sneller; Linda J Harrison; J Shawn Justement; Edgar T Overton; Mary E Petrone; D Brenda Salantes; Catherine A Seamon; Benjamin Scheinfeld; Richard W Kwan; Gerald H Learn; Michael A Proschan; Edward F Kreider; Jana Blazkova; Mark Bardsley; Eric W Refsland; Michael Messer; Katherine E Clarridge; Nancy B Tustin; Patrick J Madden; KaSaundra Oden; Sijy J O'Dell; Bernadette Jarocki; Andrea R Shiakolas; Randall L Tressler; Nicole A Doria-Rose; Robert T Bailer; Julie E Ledgerwood; Edmund V Capparelli; Rebecca M Lynch; Barney S Graham; Susan Moir; Richard A Koup; John R Mascola; James A Hoxie; Anthony S Fauci; Pablo Tebas; Tae-Wook Chun Journal: N Engl J Med Date: 2016-11-09 Impact factor: 91.245
Authors: Ann M Carias; Jeffrey R Schneider; Patrick Madden; Ramon Lorenzo-Redondo; Mariluz Araínga; Amarendra Pegu; Gianguido C Cianci; Danijela Maric; Francois Villinger; John R Mascola; Ronald S Veazey; Thomas J Hope Journal: J Immunol Date: 2021-06-23 Impact factor: 5.426
Authors: Ramon Lorenzo-Redondo; Helen R Fryer; Trevor Bedford; Eun-Young Kim; John Archer; Sergei L Kosakovsky Pond; Yoon-Seok Chung; Sudhir Penugonda; Jeffrey Chipman; Courtney V Fletcher; Timothy W Schacker; Michael H Malim; Andrew Rambaut; Ashley T Haase; Angela R McLean; Steven M Wolinsky Journal: Nature Date: 2016-01-27 Impact factor: 49.962
Authors: Pilar Mendoza; Henning Gruell; Florian Klein; Marina Caskey; Michel C Nussenzweig; Lilian Nogueira; Joy A Pai; Allison L Butler; Katrina Millard; Clara Lehmann; Isabelle Suárez; Thiago Y Oliveira; Julio C C Lorenzi; Yehuda Z Cohen; Christoph Wyen; Tim Kümmerle; Theodora Karagounis; Ching-Lan Lu; Lisa Handl; Cecilia Unson-O'Brien; Roshni Patel; Carola Ruping; Maike Schlotz; Maggi Witmer-Pack; Irina Shimeliovich; Gisela Kremer; Eleonore Thomas; Kelly E Seaton; Jill Horowitz; Anthony P West; Pamela J Bjorkman; Georgia D Tomaras; Roy M Gulick; Nico Pfeifer; Gerd Fätkenheuer; Michael S Seaman Journal: Nature Date: 2018-09-26 Impact factor: 49.962
Authors: Yehuda Z Cohen; Julio C C Lorenzi; Lisa Krassnig; John P Barton; Leah Burke; Joy Pai; Ching-Lan Lu; Pilar Mendoza; Thiago Y Oliveira; Christopher Sleckman; Katrina Millard; Allison L Butler; Juan P Dizon; Shiraz A Belblidia; Maggi Witmer-Pack; Irina Shimeliovich; Roy M Gulick; Michael S Seaman; Mila Jankovic; Marina Caskey; Michel C Nussenzweig Journal: J Exp Med Date: 2018-08-02 Impact factor: 14.307
Authors: Patricia K Riggs; Antoine Chaillon; Guochun Jiang; Scott L Letendre; Yuyang Tang; Jeff Taylor; Andrew Kaytes; Davey M Smith; Karine Dubé; Sara Gianella Journal: Curr HIV/AIDS Rep Date: 2022-10-19 Impact factor: 5.495